National Health Insurance Service

Curocell's CAR-T Therapy Rimqarto (Anbal-cel) Nears South Korean Market Launch

5 months ago

• Curocell's Rimqarto (Anbal-cel), a CAR-T therapy for relapsed or refractory large B-cell lymphoma (LBCL), is nearing market launch in South Korea. • Rimqarto demonstrated a 67.1% complete response rate in Phase 2 clinical trials, showcasing its efficacy and safety profile. • The therapy has been granted orphan drug designation and is under expedited review for approval and reimbursement in South Korea. • Curocell is also exploring global expansion opportunities for Rimqarto, including potential partnerships in South America, the Middle East, and Southeast Asia.

WISH Trial: Integrated Home Services Study for Homebound Older Adults in South Korea

6 months ago

• A multicenter, randomized encouragement design trial is underway to assess the impact of Widely Integrated Services in Home (WISH) on homebound older adults. • The WISH intervention includes interprofessional care teams providing healthcare and family counseling services through regular home visits. • The primary outcomes measured are community survival days, avoidable hospitalizations, and the rate of dying at home for participants. • The study uses a post-randomization consent design and CACE analytic methods to address potential biases and ensure real-world applicability.

South Korea Accelerates Drug Reimbursement Process with New Pilot Program

a year ago

• South Korea is implementing reforms to reduce drug reimbursement times from approximately 4 years to align more closely with other advanced nations like the US, Japan, and Germany. • A new pilot program called "Approval-evaluation-negotiation linkage system" allows simultaneous review by health authorities, with Recordati's Qarziba and Ipsen's Bylvay being the first drugs included. • The reforms include risk-sharing agreements, waivers for cost-effectiveness analysis for pediatric, rare disease, and cancer treatments, and reduced price negotiation periods from 60 to 30 days.